Therapeutic subgroup
J06 – IMMUNSERA UND IMMUNGLOBULINE
- Anatomical main group J: ANTIINFEKTIVA ZUR SYSTEMISCHEN ANWENDUNG
8Decisions
15Patient groups
Added benefit by patient group
- Considerable2
- Minor2
- Not proven11
Subgroups
- J06B IMMUNGLOBULINE 8 decisions
Decisions, newest first
- 2025-08-21BeyfortusNirsevimabConsiderable
- 2025-08-07KavigaleSipavibartNot proven: 2 of 2 patient groups
- 2025-02-20BeyfortusNirsevimabNot proven: 2 of 2 patient groups
- 2024-08-15BeyfortusNirsevimabNot proven: 2 of 2 patient groups
- 2023-11-02EvusheldTixagevimab/CilgavimabNot proven
- 2023-04-20EvusheldTixagevimab/CilgavimabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-11-03XevudySotrovimabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2018-09-20ZinplavaBezlotoxumabMinor
Data status: 2026-10-29